Bellus Health, Celtic Therapeutics Holdings L.P. deal

Bellus granted Celtic Therapeutics exclusive, worldwide rights to Kiacta eprodisate. Celtic will fund development costs through a confirmatory Phase III trial and other development activities estimat...